Giulia Franceschini

Giulia Franceschini

Auto-generated profile, based on publicly available information

Giulia Franceschini

Department of Cardiothoracic Anaesthesia, University Hospital Tor Vergata, Rome, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2022 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
MCMarco Cascella
Marco Cascella
FMFederica Monaco
Federica Monaco
DNDavide Nocerino
Davide Nocerino
ECElisabetta Chinè
Elisabetta Chinè
RCRoberta Carpenedo
Roberta Carpenedo
ACArturo Cuomo
Arturo Cuomo

3 January 2026 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
VAValentina Ajello
Valentina Ajello
SFStefano Fresilli
Stefano Fresilli
FDFilippo D'amico
Filippo D'amico
GFGiulia Franceschini
Giulia Franceschini
TATommaso Aloisio
Tommaso Aloisio
GPGianluca Paternoster
Gianluca Paternoster

Verified
Journal Article
Open access
PDF file
PFPietro Ferrara
Pietro Ferrara
EVEster Del Vescovo
Ester Del Vescovo
FIFrancesca Ianniello
Francesca Ianniello
GFGiulia Franceschini
Giulia Franceschini
LRLuciana Romaniello
Luciana Romaniello
AVAlberto Verrotti
Alberto Verrotti
Background: The first-line drug therapy for patients with nocturnal enuresis (NE) associated with nocturnal polyuria and normal bladder function is desmopressin (dDAVP). Objective: To evaluate if increasing dose of oral desmopressin lyophilisate (MELT) can improve response rates to dDAVP and is useful in enuretic children. Materials and methods: We enrolled a total of 260 children all diagnosed with NE. Enuretic children were treated with increasing MELT at a dose of 120, 180 and 240 mcg a day.Results. We included in our study a total of 237 children, 164 males (69.2%) and 73 females (30.8%) aged between 5 and 18 years (mean age 10.32 ± 2.52 years). Of the 237 patients enrolled in the study and treated with MELT 120 mcg, a full response was achieved in 135 (56.9%). A partial response was achieved in 21 (8.9%) patients, therefore the dose was increased up to 180 mcg, with further improving symptoms (14.3%) or full response (9.5%), and up to 240 mcg, without usefulness. Conclusions: MELT at the dose of 120 mcg resulted efficacy and safety; the increased dose up to 180 mcg resulted poorly efficacy; finally, the further increase up to 240 mcg did not improve the symptoms with the increased risk of side effects.

1 September 2022 in Minerva Psychiatry
Verified
Journal Article
Closed access
PFPietro Ferrara
Pietro Ferrara
GFGiulia Franceschini
Giulia Franceschini
MPMaria F. Pennarola
Maria F. Pennarola
VQVito A. Quartulli
Vito A. Quartulli
EMElena Malavolta
Elena Malavolta
AIAndrea Ianni
Andrea Ianni
Article: Psychological impact of the quarantine upon the Italian pediatric population - Minerva Psychiatry 2022 September;63(3):231-6 - Minerva Medica - Journals